Latest Industry Insights

To learn more about new technologies being developed for drug discovery and cell therapy, Technology Networks spoke to bit.bio's Dr. Farah Patell-Socha and Furqan Iqbal.

In this interview, Gregory J. McKenzie, PhD, discusses the impact of antibiotics, the introduction of new bacteria into the microbiome and the potential of human breast milk-based therapeutics.

The science and medicine worlds are experiencing a new revolution, and this time the protagonist is the mRNA molecule. In this article, we explore why bioplatforms support this revolution.

Technology Networks learns about the "unusual" spread of the monkeypox virus in non-endemic countries, possible vaccination strategies against the virus and if there are effective treatments available.

Research is advancing exciting areas of science at an unprecedented pace, but the disposable materials, powered equipment and shipping associated with experiments, sample storage and transport of reagents contribute to high energy consumption and significant waste. How are researchers bringing sustainability to scientific discovery?

In April 2022, Cancer Research UK unveiled Cancer Research Horizons, its new approach to driving innovation in the field. Technology Networks had the opportunity to speak with two members of Cancer Research Horizon’s executive leadership team to learn more about some of the cutting-edge experimental capabilities that will be used to interrogate cancer biology more thoroughly.

We spoke to Geoff Winkett and Michel van den Berge from Agilent, about the concerns they hear from their customers in the pharmaceutical and biopharmaceutical sector and how they are helping to address them.

Technology Networks spoke to Jason Ornstein and Barry Holtz to learn how Synshark and Phylloceuticals are working together to address current challenges associated with squalene supply and access.

Technology Networks had the pleasure of talking to Wilfredo Marín to learn more about OPC UA and how it is suited to biobanking and cell and gene therapy development.

While oncolytic virus (OV) therapy has garnered increasing attention from the cancer research community, this therapeutic strategy doesn’t come without its challenges, as a patient’s immune system can sometimes mount a response to the OVs before they reach their intended target. To address this, Calidi Biotherapeutics has developed cell-based platforms to shield OVs from the immune system, so that they can effectively target and destroy the cancer cells.